Millionaire Son in Law Chapter 1656
Please read this chapter.
- Kobayashi Pharmaceutical faces a competitive threat to its main product.
- Increased investment in research and development is necessary for the company.
- A significant fund of one billion USD is needed to improve the drug R&D laboratory.
Kobayashi Pharmaceutical faces a significant challenge to its flagship product. The company needs to increase R&D investment to stay competitive. A substantial fund is required to upgrade the drug research and development laboratory.
Kobayashi’s Weisan is the flagship product of Kobayashi Pharmaceutical, and most of its revenue and profits are supported by this medicine.
If it is really beaten by JX Weisan, then Kobayashi Pharmaceutical’s vitality will definitely be greatly injured.
So someone asked Masayoshi Kobayashi: “President, we can’t just wait and die like this! Do you have any good solutions?”
Kobayashi Masayoshi said: “There is also a way to deal with it, that is, we must increase investment in drug research and development, and we must quickly upgrade our current products. If our Kobayashi Weisan can surpass JX in terms of efficacy. Stomach market must still be ours!”
The person in charge of R&D opened the mouth and said: “My lord, if you want to increase investment in R&D, you need a huge budget. The company was sacked of a lot of money some time ago. Can it still afford it now?”
Masayoshi Kobayashi said smoothly: “This is what I’m about to tell you. Our current cash flow is not very good. The investment in the production base in Osaka costs a lot, coupled with the previous accidental losses, which leads us to get it now. The funds invested in research and development are already less than 50 million USD, so my idea is to raise a fund as soon as possible, with at least one billion USD to upgrade our drug R&D laboratory!”